Adverse effects observed in trials include: Nausea and vomiting particularly during dose escalation Diarrhoea or constipation Decreased appetite Injection site reactions Fatigue and dizziness Gallbladder-related events (including gallstones), consistent with effects observed with other GLP-1based therapies [9] Rare cases of pancreatitis , a risk associated with the GLP-1 receptor agonist class [10] [3] Because retatrutide is not licensed in the UK, the MHRA has not issued specific prescribing or dosing guidance for this compound
User experiences vary widely
[1] [4] Whilst Rybelsus is generally well-tolerated, patients occasionally report changes in urine odour during treatment
Based on available research and user experience, REGEN appears safe for cycles up to 12 weeks at standard doses
Rapamycin and Its Role in Longevity Huberman also delves into rapamycin, an mTOR (mechanistic target of rapamycin) inhibitor that has been shown to extend the lifespan of various animal models
Additional non-oral contraception is advised for 4 weeks after starting treatment and for 4 weeks after each dose increase If pancreatitis is suspected (severe, persistent abdominal pain with or without vomiting), stop Mounjaro immediately and seek urgent medical assessment Mounjaro is not indicated for type 1 diabetes or diabetic ketoacidosis The medication is not recommended during pregnancy or breastfeeding Patients should report any suspected side effects via the MHRA Yellow Card Scheme